Impact of absent in melanoma 2 on head and neck squamous cell carcinoma development
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf224 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Dakota M Reinartz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunobiology, University of Arizona, Tucson, AZ 85724, United States. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, DNA-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Beta Psi Cancer Research Grant, NIA NIH HHS.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) constitutes 90% of head and neck cancers. HNSCC development is linked to chronic inflammation, while established HNSCC tumors are often immune suppressive. However, both occur through mechanisms that are not fully understood. The cytosolic double-stranded DNA sensor absent in melanoma 2 (AIM2) is an inflammasome-forming protein that also has inflammasome-distinct roles in restricting tumorigenesis by limited PI3K signaling. Here, we used an experimental mouse model of HNSCC, involving treatment of wild-type (WT) and Aim2−/− mice with the carcinogen 4NQO in drinking water. Compared with WT mice, 4NQO-treated Aim2−/− mice exhibited larger tumors and increased tissue dysplasia. 4NQO-treated WT and Aim2−/− mice displayed similar tongue Il6, Tnf, Il1b, Il12, and Il10 expression and no consistent differences in PI3K or inflammasome activation, suggesting AIM2 may not regulate these factors during HNSCC. Instead, Ifng and Irf1 was elevated in 4NQO-treated Aim2−/− mice, suggesting that AIM2 restricts IFN-γ. In line with this, RNA sequencing of total tongue RNA from 4NQO-treated mice revealed that Aim2−/− mice had enhanced expression of genes related to the major histocompatibility complex protein complex, cell killing, and T cell activation compared with WT mice. We also observed increased macrophage infiltration into the tongue epithelium of 4NQO-treated Aim2−/− mice and an increased M1:M2 macrophage ratio. Using Aim2−/−/Rag1−/− double-deficient animals, we found that the adaptive immune compartment was necessary for the enhanced tumorigenesis during AIM2 deficiency. These findings suggest that AIM2 limits the progression of oral tumor development partially through regulating IFN-γ and adaptive immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunobiology, University of Arizona, Tucson, AZ 85724, United States.
- University of Arizona Cancer Center, Tucson, AZ 85724, United States.
- Department of Otolaryngology - Head and Neck Surgery, University of Arizona, Tucson, AZ 85724, United States.
- Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ 85724, United States.
- Department of Clinical Translational Sciences, University of Arizona, Tucson, AZ 85724, United States.
ORCID-Profile: Dakota M Reinartz, Stephanie L Tribble
Förderung
- NCI NIH HHS
- Beta Psi Cancer Research Grant
- NIA NIH HHS
- NIDCR NIH HHS
- Institutional Research
- NIH HHS
- National Institute of Dental Craniofacial Research
- American Cancer Society
Zitieren
APA
Reinartz, D. M., Escamilla-Rivera, V., Shao, M., Tribble, S. L., Caulin, C., & Wilson, J. E. (2025). Impact of absent in melanoma 2 on head and neck squamous cell carcinoma development. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf224
Vancouver
Reinartz DM, Escamilla-Rivera V, Shao M, Tribble SL, Caulin C, Wilson JE. Impact of absent in melanoma 2 on head and neck squamous cell carcinoma development. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf224
BibTeX
@article{Reinartz2025,
author = {Reinartz, Dakota M and Escamilla-Rivera, Vicente and Shao, Manlin and Tribble, Stephanie L and Caulin, Carlos and Wilson, Justin E},
title = {Impact of absent in melanoma 2 on head and neck squamous cell carcinoma development},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf224}
}
EUVIMED